Bavarian Nordic (OTCMKTS:BVNRY) Sees Strong Trading Volume – Should You Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw strong trading volume on Thursday. 18,499 shares changed hands during mid-day trading, an increase of 475% from the previous session’s volume of 3,216 shares. The stock last traded at $10.81 and had previously closed at $11.1095.

Bavarian Nordic Stock Down 2.7%

The stock has a market cap of $2.57 billion, a P/E ratio of 10.92 and a beta of 1.20. The firm’s 50-day moving average is $10.22 and its two-hundred day moving average is $9.86.

Bavarian Nordic (OTCMKTS:BVNRY) last released its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a net margin of 24.36% and a return on equity of 11.97%. The business had revenue of $316.47 million for the quarter.

Bavarian Nordic Company Profile

Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.

Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.